Delaware
|
56-2020050
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(I.R.S. Employer
Identification No.)
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☐
|
Item 8.
|
Exhibits.
|
Exhibit No.
|
Exhibit Description
|
4.1
|
|
4.2
|
|
4.3
|
|
4.4
|
|
4.5
|
|
4.6
|
|
4.7
|
|
4.8
|
|
4.9
|
|
4.10
|
|
4.11
|
|
5.1*
|
|
23.1*
|
|
23.2*
|
|
24.1*
|
|
99.1
|
|
107*
|
Gyre Therapeutics, Inc.
|
||
By:
|
/s/ Han Ying
|
|
Name:
|
Han Ying, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Signature
|
Title
|
Date
|
|||
/s/ Han Ying
|
Chief Executive Officer and Director (Principal Executive Officer)
|
March 27, 2024
|
|||
Han Ying, Ph.D.
|
|||||
/s/ Ruoyu Chen
|
Chief Financial Officer (Principal Financial and Accounting Officer)
|
March 27, 2024
|
|||
Ruoyu Chen
|
|||||
|
Chairman of the Board of Directors
|
|
|||
Ying Luo, Ph.D.
|
|||||
/s/ Gordon G. Carmichael
|
Director
|
March 27, 2024
|
|||
Gordon G. Carmichael, Ph.D.
|
|||||
/s/ Renate Parry
|
Director
|
March 27, 2024
|
|||
Renate Parry, Ph.D.
|
|||||
/s/ Thomas Eastling
|
Director
|
March 27, 2024
|
|||
Thomas Eastling
|
|||||
/s/ Nassim Usman
|
Director
|
March 27, 2024
|
|||
Nassim Usman, Ph.D.
|
|||||
Director | |||||
Songjiang Ma | |||||
/s/ Rodney L. Nussbaum | Director | March 27, 2024 | |||
Rodney L. Nussbaum |